Sinopharm : ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE SIX MONTHS ENDED 30 JUNE 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF

SINOPHARM (CNCM LTD)

FOR THE SIX MONTHS ENDED 30 JUNE 2020

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 19 August 2020 (the "Announcement") in relation to the interim report for the six months ended 30 June 2020 (the "Reporting Period") of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the six months ended 30 June 2020 as set out in the Announcement.

1

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

Unit: Yuan

Currency: RMB

Total assets

Net assets attributable to shareholders of listed company

Net cash flow arising from operating activities

Revenue

Net profit attributable to shareholders of the listed company

Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses

As at the end of this		Increase/decrease as
As at the end of last year	compared with the end
Reporting Period
		of last year (%)
23,502,099,040.05	24,193,651,172.80	-2.86
10,685,602,013.21	10,537,090,367.14	1.41
		Increase/decrease as
The Reporting Period	The same period of last	compared with the
(January to June)	year	same period of last
		year (%)
911,707,964.14	691,265,981.72	31.89
		Increase/decrease as
The Reporting Period	The same period of last	compared with the
(January to June)	year	same period of last
		year (%)
17,531,054,821.22	21,022,078,606.53	-16.61
619,838,383.32	754,610,594.59	-17.86
569,257,129.19	728,312,439.26	-21.84

Weighted average return on net assets (%)

Weighted average return on net assets after deducting non-recurring gains and losses (%)

Basic earnings per share (RMB/Share)

Diluted earnings per share (RMB/Share)

Basic earnings per share after deducting non- recurring gains and losses (RMB/Share)

5.80	7.94	decreased by 2.14
percentage points
5.32	7.66	decreased by 2.34
percentage points
0.8215	0.9872	-16.78
0.8215	0.9872	-16.78
0.7545	0.9528	-20.81

2

By order of the Board

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC

19 August 2020

As at the date of this announcement, the executive Directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive Directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive Directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies
  Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

3